超越胸苷酸合成酶和二氢叶酸还原酶：非编码微小RNA在抗癌化疗耐药中的作用
Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance.
作者信息
Ju Jingfang
机构信息
Translational Research Laboratory, Department of Pathology, State University of New York at Stony Brook, Stony Brook, NY 11794-8691, USA.
出版信息
Curr Enzym Inhib. 2012 Sep 1;8(2):118-123. doi: 10.2174/157340812800793228.
Chemoresistance is one of the major reasons for the failure of anticancer chemotherapy in treating advanced stage cancer. The mechanism of chemoresistance to fluoropyrimidines and antifolates has been extensively investigated in the past 40 years. It has been well established that thymidylate synthase (TYMS, TS) and dihydrofolate reductase (DHFR) are two major targets for fluoropyrimidines and antifolates, respectively. The regulatory mechanism of TS and DHFR expression is rather complex involving transcriptional, post-transcriptional and translational regulations. Our recent understanding of the chemoresistance mechanism has been extended beyond the simple one target/drug view. In this review, we will focus on the recent advancement of non-coding microRNAs (miRNAs) in contributing to the regulations of TS and DHFR expression, and to the chemoresistance mechanism of fluoropyrimidines and antifolates.
化疗耐药是晚期癌症抗癌化疗失败的主要原因之一。在过去40年里，对氟嘧啶和抗叶酸剂化疗耐药机制进行了广泛研究。已经明确胸苷酸合成酶（TYMS，TS）和二氢叶酸还原酶（DHFR）分别是氟嘧啶和抗叶酸剂的两个主要靶点。TS和DHFR表达的调控机制相当复杂，涉及转录、转录后和翻译调控。我们最近对化疗耐药机制的理解已超越了简单的单靶点/药物观点。在本综述中，我们将重点关注非编码微小RNA（miRNA）在调控TS和DHFR表达以及氟嘧啶和抗叶酸剂化疗耐药机制方面取得的最新进展。
Zotero 插件